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Abstract Protein phosphorylation is the regulatory mechanism 
of many cellular events in response to changes in metabolic activ- 
ity and environmental conditions. Seeing that PKC and TdT 
levels in cells are both regulated by PMA, we sought particularly 
intriguing to investigate TdT phosphorylation in vivo, utilizing 
KM-3 cells, a TdT-positive human pre-B cell ine treated with 
PMA and in vitro, employing purified PKC and human recombi- 
nant TdT. Our data show that TdT is a substrate for PKC 
activity, suggesting that TdT phosphorylation could play a key 
role in the pathway affecting the control of gene transcription and 
protein synthesis during lymphoid cells differentiation. 
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1. Introduction 
Terminal deoxynucleotidyl transferase (TdT) is a 'creative' 
DNA polymerase found only in lymphoid cells at early stages 
of differentiation and in corresponding leukemic cells [1,2]. It 
has long been thought to play a role in the generation of so- 
matic diversity in primitive T and B cells [3], without a general 
mutagenic effect [4]. Recent gene disruption experiments in 
mice have shown that TdT is responsible for creating N region 
diversity [5,6] in immunoglobulin and T cell receptor genes. It 
has been previously proved that in KM-3 cells the TdT synthe- 
sis can be downregulated by phorbol ester treatment [7,8]. The 
complete amino acid sequence of human TdT has been ob- 
tained by DNA-cloning and shows that the first 17 N-terminal 
residues contain a potential nuclear localization sequence and 
phosphorylation sites [9]. Experiments on labeling of human 
lymphoblastoid cells with [32p]phosphate showed that TdT can 
be phosphorylated by a cAMP-dependent protein kinase with 
an increase of TdT activity [10]. In vitro phosphorylation of 
TdT by the catalytic subunit of cAMP-dependent protein ki- 
nase results in phosphorylation within the first 17 N-terminal 
residues [11]. Protein kinase C (PKC) might be involved in the 
regulation of TdT since it is present and operates in the nucleus 
of most cell types [12 15]. PKC is physiologically regulated by 
diacylglycerol and Ca 2+ and can be activated by phorbol esters 
[16-19]. In this study, we have demonstrated in vitro phospho- 
rylation of human recombinant TdT by purified PKC and in 
vivo phosphorylation of TdT in KM-3 cells after treatment by 
*Corresponding author. Fax: (39) (871) 574 361. 
PMA, thus, raising the possibility that PKC might modulate 
TdT function and/or localization. 
2. Materials and methods 
Enzymatically active human recombinant TdT (predominantly 58- 
kDa species) was purified from recombinant baculovirus-infected insect 
cells [20]. Protein A sepharose-conjugated monoclonal ntibody against 
TdT protein was from Supertech (Rockville, MD). Peroxidase-conju- 
gated secondary antibodies and normal goat serum were from Litton 
Bionetics (Kensington, MD). [~'-32p]ATP (5000 Ci/mmol) and ~/-32po 4 
orthophosphate in aqueous olution (HCl-free, 10 mCi/ml) were ob- 
tained from Amersham (UK). 
2.1. Cell culture 
KM-3 cell line is a TdT-positive human pre-B cell line originally 
described by Schneider et al. [21]. Cells were grown in RPMI-1640 
medium supplemented with 10% FBS, 4 mM L-glutamine, 100 mM 
Na-pyruvate and 25 mM HEPES. Cell cultures at a density of 2.5 × 105/ 
ml, with >98% viability by Trypan blue exclusion test, were used for 
experiments. For induction experiments, the cells were suspended in 
complete medium in the presence of 20 ~tM PMA prepared as previ- 
ously described [8] and cultured for a maximum of 4 h. 
2.2. TdT in vivo phosphorylation 
3 × l07 of untreated, PMA-treated and PMA-treated KM-3 cells in 
the presence of 50/IM bisindolylmaleimide hydrochloride as PKC in- 
hibitor [22] were incubated in 3 ml DMEM phosphate-free medium 
containing 10% FCS and 0.5 mCi/ml/1 × 106 32po 4 for 4 h at 37°C. 
Washed cells were homogenized in 1 ml P~ 0.2 M (pH 7.4). Immunopre- 
cipitation was performed by adding to 2 ml of sample 10 pl of conju- 
gated protein A sepharose gel monoclonal antibody antihuman TdT, 
at the concentration of 2 mg/ml, and then incubated at cold room 
overnight. The immunoprecipitate where washed after spinning. Pro- 
tein concentration was determined by the Bio-Rad protein assay (Bio- 
Rad Laboratories, Hercules, CA), consequently, the same amount of 
proteins has been electrophoresed as standard procedure. After SDS- 
polyacrilamide gel electrophoresis, the samples were electroblotted on 
nitrocellulose. Nitrocellulose paper was treated as described [23] for 
immunological detection of TdT and autoradiographed on Kodak X- 
OMAT film. 
2.3. TdT in vitro phosphorylation 
10 pg recombinant TdT proteins were phosphorylated with 0.07 U 
PKC at 30°C for 10 min in the presence of 5 mM MgC12, 3 mM 
dithiothreitol, 100 ~M vanadate, 250 ~M CaCl2, 100/~g/ml phosphati- 
dylserine and 4/~g/ml diacylglycerol r20 ~tM PMA as PKC activator. 
As specific PKC inhibitor, we used 50 ,uM bisindolylmaleimide hydro- 
chloride. The reactions were stopped with appropriate volumes of 
4 × sample buffer (0.25 M Tris-HCl (pH 6.8), 8% SDS, 40% glycerol, 
20% fl-mercaptoethanol, 0.005% Bromophenol b ue), boiled for 5 rain 
and electrophoresed on 10% acrylamide/ 0.1% SDS according to 
Laemmli (1970). The proteins were electroblotted on nitrocellulose, 
stained with Ponceau S and autoradiographed on Kodak X-OMAT 
film. PKC was obtained from rat brain essentially as described by 
Kikkawa et al. [24], omitting the final chromatographic step. 
For in vivo and in vitro experiments, the same antibodies were used. 
Mouse monoclonal and rabbit polyclonal antihuman TdT antibodies 
were prepared and their specificity established as described [25,26]. 
Protein A sepharose monoclonal anti-TdT specificity has been verified 
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in our experiments and as previously reported [25 28]. We did not 
obtain cross-reactions with o er proteins (data not shown). 
3. Results and discussion 
Since TdT and PKC colocalize in the interchromatin do- 
mains ([12,15,23,29-33] and pers. data), we tested TdT as a 
substrate for PKC. The results obtained by in vitro phosphoryl- 
ation of recombinant human TdT with partly purified PKC is 
shown in the autoradiography in Figs. 1 and 2. The Ponceau 
S-stained nitrocellulose suggests that recombinant human TdT 
is predominantly 58-kDa species (Fig. 1). A trace of 56-kDa 
species present probably represents ranslation at an alternate 
start site on the TdT mRNA in the baculovirus expression 
system. The autoradiogram (Fig. 1) shows that both 58- and 
56-kDa peptides are phosphorylated by PKC. Some minor 
autophosphorylation bands are also present, including the 80- 
kDa native PKC, as revealed in both gel lanes. We have also 
carried out in vitro phosphorylation f calf thymus TdT with 
PKC and found that besides the 58- and 56-kDa peptides, lower 
molecular weight species of calf thymus TdT as well as the c~- 
and fl-subunits of the low molecular weight form of calf thymus 
TdT are also phosphorylated byPKC (data not shown). These 
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Fig. 1. In vitro phosphorylation f recombinant human TdT by PKC. 
(A) Autophosphorylation la e containing complete mixture except 
TdT. Molecular weight markers are in kDa. 
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Fig. 2. In vitro phosphorylation assay. Lane A shows a over- 
phosphorylated band (58 kDa) undetectable in the presence of PKC 
inhibitor (lane B). Lane C documents a sample containing only PKC 
and TdT. Molecular weight markers are expressed in kDa. 
results induce to suppose that PKC phosphorylates TdT at 
multiple sites, suggesting the presence of several phosphoryla- 
tion sites along the peptide [9,28]. The autoradiogramm re- 
ported in Fig. 2, lane A displays the TdT in vitro phosphoryl- 
ation experiments in the presence of 20/ IM PMA instead of 
DG. Under this condition, is possible to observe a strong 
phosphorylated 58-kDa band corresponding to TdT protein. 
Lane B shows the phosphorylation assay in the presence of 
bisindolylmaleimide hydrochloride as specific PKC inhibitor. 
Lane C reports TdT phosphorylation assay performed in ab- 
sence of Ca 2+, phospholipids and PMA. In these experimental 
conditions, both lane B and C do not show significant TdT 
phosphorylation processes. PMA-treated KM-3 lymphoblastic 
leukemic ells were labeled in vivo with 32po 4. TdT was recov- 
ered from the lysate by immunoprecipitation, using a specific 
monoclonal antibody Protein A-conjugated (Fig. 3). SDS-poly- 
acrylamide gel electrophoresis followed by autoradiography 
revealed a major labeled band of 58 kDa corresponding, as 
observed in vitro phosphorylation, to the high molecular 
weight form of TdT (Fig. 3, section B, lane a). Untreated (lane 
b) and PMA-treated samples cultured in the presence ofa PKC 
inhibitor (lane c) did not show phosphorylated peptides. In 
O. Trubiani et al./FEBS Letters 374 (1995) 367-370 
a b c a b C 
58.-.. 
56 - -  
Fig. 3. (A) Immunoblotting analysis showing the pr sence of 58- and 
56-kDa TdT in PMA-treated cells (a), untreated KM-3 cells (b) and in 
KM-3 cells treated with PMA and bisindolylmaleimide (c).(B) In vivo 
phosphorylation f KM-3 cells upon PMA treatment. I  is possible to 
observe aphosphorylated 58-kDa TdT in PMA-treated KM-3 cells (a). 
Untreated cells do not show phosphorylated peptides (b). KM-3 cells 
treated with both PMA and Bisindolylmaleimide id not show the 
presence of phosphorylated T T (c). Molecular weight markers are 
expressed in Kda. 
Fig. 3, section A, we report Western blot analysis of the same 
samples reported in section B. Lines am display the presence 
of 56- and 58-kDa TdT protein. It has been recently proved that 
PKC can be translocated, after induction of inositol lipid 
breakdown, to the nucleus [31,32] and can be downregulated 
in KM-3 cells after 24 h of PMA treatment (pers. data). Among 
the diversity of nuclear targets of PKC, beside histones, lamin- 
ins have been reported to be phosphorylated [33,34]. It is inter- 
esting that the sites of laminin phosporylation by PKC are the 
same in vivo an in vitro. DNA polymerase ~ has also been 
reported to be phosphorylated in vitro by PKC [35] and in vivo, 
the enzyme undergoes phosphorylation dependent on 
phosphatidyl inositol mono and diphosphate [36]. Other nu- 
clear enzymes affecting DNA structure and function, such as 
DNA topoisomerase II, could be substrates for PKC [37] as 
well as the nucleoside phosphatase that mediates mRNA trans- 
port out of the nucleus [38]. The role of PKC in T cell activation 
has recently been described and this contributes to understand- 
ing the involvement of PKC in specific biological processes, 
including regulation of the immune responses [39]. Terminal 
transferase plays a key role in the immune differentiation events 
and has been described that extracellular stimuli as phorbol 
ester modulate the presence of TdT in prelymphocytes and can 
induce the PKC translocation into the nucleus, the conven- 
tional site of TdT localization. The data reported in this paper 
prove that the terminal transferase is a biological nuclear sub- 
strate for PKC- mediated phosphorylation process. Therefore, 
we propose that the phosphorylation f TdT might be an early 
step in the overall process of lymphoid ifferentiation. Since the 
protein kinase C consists of multiple isoenzymes with possibly 
distinctly different biological functions, more extensive fforts 
are being made for full understanding the specific PKC isoform 
involved in TdT phosphorylation process. 
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